# To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation

> **NCT05541822** · PHASE2 · RECRUITING · sponsor: **Abion Inc** · enrollment: 178 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** Vabametkib
- **DRUG:** Lazertinib

## Key facts

- **NCT ID:** NCT05541822
- **Lead sponsor:** Abion Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-17
- **Primary completion:** 2029-02
- **Final completion:** 2029-02
- **Target enrollment:** 178 (ESTIMATED)
- **Last updated:** 2025-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05541822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05541822, "To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05541822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*